Transparent vs. Traditional PBMs: What’s the Best Choice?
By: Kevin Kobielski, President of Navion In the world of pharmacy benefits, “transparency” has become a golden word—implying clarity, fairness, […]
Articles
The Rise of Direct-to-Consumer Drug Pricing
Direct-to-consumer pharmacy programs aren’t new—but they’re about to get a lot bigger. Pharmaceutical manufacturers offer select medications directly to patients at flat or discounted
Navion Update: Pfizer Announces Most Favored Nation (MFN) Drug Pricing in the U.S.
On September 30, 2025, during a joint White House press conference, Pfizer announced a landmark pricing agreement to lower drug
Q3 2025 FDA Drug Approvals: Wegovy, HIV PrEP, RSV Protection & More
By Beckie Fenrick, PharmD, MBA and Jason Peterson, RPh The FDA’s Q3 2025 approvals mark a pivotal quarter, with new
Pharmacy Spend: Why Clinical Strategy Is the New Cost Strategy
By: Kevin Kobielski, President of Navion For years, the pharmacy benefits conversation has revolved around unit costs, rebates, and discounts.
Why Regular Market Checks Are One of the Smartest Moves in Pharmacy Oversight
By: Kevin Kobielski, President of Navion Pharmacy contracts don’t age gracefully. What may have been a strong deal years ago
The Current State of ADHD Medications: Shortages, Safety Risks, and Solutions for Plan Sponsors
By Jason Peterson, RPh; Beckie Fenrick, PharmD, MBA; and Emily Crisano, PharmD, RPh August brings the familiar back-to-school rush—a stressful
